Abstract: The invention relates to the use of dimethylated ?-cyclodextrins, particularly DIMEB and RAMEB, as agents for promoting the penetration of vitamin A or its cosmetically or dermatologically acceptable esters into the epidermis, and their retention in the skin, for the preparation of a cosmetic or dermatological composition containing a combination of vitamin A or at least one of its cosmetically or dermatologically acceptable esters with said dimethylated ?-cyclodextrins. It further relates to novel cosmetic or dermatological compositions containing these combinations of dimethylated ?-cyclodextrins and vitamin A or vitamin A esters, particularly in the form of inclusion complexes. It further relates to uses of these compositions in the field of cosmetics or dermatology.

Abstract: The invention provides cyclodextrin derivatives that may be used to transport hydrophobic molecules for pharmaceutical or cosmetic applications, by forming organised systems in an aqueous medium, alone or with phospholipids. The cyclodextrin derivatives of the present invention have the formula: in which, R1 represents a steroid, R2 represents an alkyl or aryl group, substituted if applicable, R3 represents H or R2, all the R4 represent OR2, or one of the R4 represents —NHCO(CH2)mCONHR1, m is an integer ranging from 1 to 8, and n is equal to 5, 6 or 7.

Abstract: The invention relates to radio-pharmaceutical compositions that include an inclusion complex of a cyclodextrin and a radio-halogenated fatty acid.These complexes include a cyclodextrin such as .beta.-cyclodextrin, .gamma.-cyclodextrin and their derivatives, and a radio-halogenated fatty acid, in particular a fatty acid labelled with radioactive iodine such as 16-iodo 3-methyl hexadecanoic acid suitable for the examination of the myocardium by scintigraphy.The cyclodextrin allows the fatty acid to dissolve in aqueous solution without any addition of human blood albumin, while further improving the biodistribution of the fatty acid and its stability to heat.

Abstract: The invention relates to derivatives of cyclodextrins, their preparation and their use for incorporating hydrophobic molecules into organized surfactant systems. These derivatives of cyclodextrins are in accordance with the formula: ##STR1## in which R.sup.1 represents a group protecting an amine function, the R.sup.2, which can be the same or different, represent OH or NH--CH.sub.2 m--NHR.sup.1,m being an integer from 2 to 18 and n is equal to 5, 6 or 7.

Abstract: The invention relates to the use of natural cyclodextrins and their derivatives for the solubilization of platelet anti-aggregating agents from the family of Ginkgolides.The cyclodextrins used comply with the formula: ##STR1## in which n is equal to 6, 7 or 8 and the R.sup.1, which can be the same or different, represent OH or SR.sup.2 with R.sup.2 representing a group derived from a monosaccharide or an oligosaccharide.The Ginkgolide is preferably Ginkgolide B.

Abstract: The invention relates to novel cyclodextrin derivatives according to formula: ##STR1## in which R.sup.1 represents OH or NH(CH.sub.2).sub.p OH, n is equal to 5, 6 or 7 and p is an integer from 2 to 6, it being possible for the p to be different when one or more of the R.sup.1 represent NH(CH.sub.2).sub.p OH.These derivatives can be used for solubilizing hydrophobic chemical compounds such as active principles in an aqueous medium by the formation of inclusion complexes therewith.

Abstract: The invention relates to the use of mono-3,6-anhydrocyclodextrins for solubilizing a hydrophobic compound and for controlling the purity of an enantiomer.The mono-3,6-anhydrocyclodextrin complies with the following formula: ##STR1## in which n is equal to 5, 6 or 7. Preferably n is equal to 6. The hydrophobic compound can be a steroid such as prednisolone.